[{"address1": "321 Summer Street", "address2": "Suite 400", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857 330 4340", "website": "https://www.inozyme.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Dr. Douglas A. Treco Ph.D.", "age": 66, "title": "CEO & Chairman", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 591875, "exercisedValue": 0, "unexercisedValue": 116098}, {"maxAge": 1, "name": "Mr. Axel  Bolte M.B.A., M.Sc.", "age": 52, "title": "Co-Founder, Senior Advisor & Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1158083, "exercisedValue": 0, "unexercisedValue": 1257688}, {"maxAge": 1, "name": "Mr. Sanjay S. Subramanian M.B.A., M.S.", "age": 47, "title": "Senior VP, CFO, Principal Accounting Officer & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 626233, "exercisedValue": 0, "unexercisedValue": 47925}, {"maxAge": 1, "name": "Dr. Matthew  Winton Ph.D.", "age": 46, "title": "Senior VP & COO", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 526431, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Demetrios  Braddock M.D., Ph.D.", "title": "Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Soojin  Kim Ph.D.", "title": "Senior VP & Chief Technical Operations Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yves  Sabbagh Ph.D.", "title": "Senior VP, Chief Scientific Officer & Chair of the Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stefan  Riley", "title": "Director of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gayle  Gironda", "title": "Senior VP & Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen J. Di Palma M.B.A.", "age": 65, "title": "Consultant", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.2, "open": 1.19, "dayLow": 1.16, "dayHigh": 1.22, "regularMarketPreviousClose": 1.2, "regularMarketOpen": 1.19, "regularMarketDayLow": 1.16, "regularMarketDayHigh": 1.22, "payoutRatio": 0.0, "beta": 1.287, "forwardPE": -0.7407408, "volume": 466484, "regularMarketVolume": 466484, "averageVolume": 811257, "averageVolume10days": 595070, "averageDailyVolume10Day": 595070, "bid": 1.18, "ask": 1.23, "bidSize": 4, "askSize": 2, "marketCap": 77088240, "fiftyTwoWeekLow": 1.16, "fiftyTwoWeekHigh": 7.795, "fiftyDayAverage": 1.9069, "twoHundredDayAverage": 3.9663, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -7727762, "profitMargins": 0.0, "floatShares": 35862091, "sharesOutstanding": 64240200, "sharesShort": 4301097, "sharesShortPriorMonth": 3854935, "sharesShortPreviousMonthDate": 1736899200, "dateShortInterest": 1739491200, "sharesPercentSharesOut": 0.067, "heldPercentInsiders": 0.013099999, "heldPercentInstitutions": 0.92509, "shortRatio": 4.98, "shortPercentOfFloat": 0.072399996, "impliedSharesOutstanding": 64240200, "bookValue": 1.29, "priceToBook": 0.93023264, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -96494000, "trailingEps": -1.55, "forwardEps": -1.62, "enterpriseToEbitda": 0.078, "52WeekChange": -0.8083067, "SandP52WeekChange": 0.14239466, "quoteType": "EQUITY", "currentPrice": 1.2, "targetHighPrice": 30.0, "targetLowPrice": 11.0, "targetMeanPrice": 18.0, "targetMedianPrice": 15.5, "recommendationMean": 1.44444, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 8, "totalCash": 131608000, "totalCashPerShare": 2.049, "ebitda": -98893000, "totalDebt": 46792000, "quickRatio": 7.174, "currentRatio": 7.683, "debtToEquity": 56.52, "returnOnAssets": -0.35691002, "returnOnEquity": -0.79419, "freeCashflow": -55929500, "operatingCashflow": -91206000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "INZY", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Inozyme Pharma, Inc.", "marketState": "CLOSED", "longName": "Inozyme Pharma, Inc.", "corporateActions": [], "exchange": "NMS", "messageBoardId": "finmb_568596329", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "postMarketTime": 1740787728, "regularMarketTime": 1740776401, "fiftyDayAverageChange": -0.7069, "fiftyDayAverageChangePercent": -0.37070638, "twoHundredDayAverageChange": -2.7663, "twoHundredDayAverageChangePercent": -0.697451, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-07-24", "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1595597400000, "postMarketChangePercent": 0.833332, "postMarketPrice": 1.21, "postMarketChange": 0.00999999, "regularMarketChange": 0.0, "regularMarketDayRange": "1.16 - 1.22", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 811257, "fiftyTwoWeekLowChange": 0.04000008, "fiftyTwoWeekLowChangePercent": 0.03448283, "fiftyTwoWeekRange": "1.16 - 7.795", "fiftyTwoWeekHighChange": -6.5950003, "fiftyTwoWeekHighChangePercent": -0.8460552, "fiftyTwoWeekChangePercent": -80.83067, "earningsTimestampStart": 1741609800, "earningsTimestampEnd": 1741955400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.55, "epsForward": -1.62, "epsCurrentYear": -1.51, "priceEpsCurrentYear": -0.79470205, "regularMarketChangePercent": 0.0, "regularMarketPrice": 1.2, "displayName": "Inozyme Pharma", "trailingPegRatio": null, "__fetch_time": "2025-03-01"}]